Roche (RHHBY) receives the FDA priority review for a marketing application seeking U.S. approval of its oral multiple ...

The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Quantum BioPharma Ltd. QNTM on Tuesday said it is partnering with the clinical research division of Thermo Fisher Scientific ...

ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple ‌sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

LONDON, Sept 1 (Reuters) - (This Sept 1 story has been corrected to say that remibrutinib is approved to treat only one skin condition, not two, in paragraph 11.) Swiss drugmaker Novartis (NOVN.S), ...

Sentara will be out of network for Anthem Medicare Advantage on Jan. 1. Hampton Roads members can check doctors and switch plans by Dec. 7. UnitedHealthcare Will Leave Georgia's ACA Marketplace in ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial for the most common form of the disease. The Swiss pharmaceutical company said Monday ...